Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Delmed

Executive Summary

Shareholders in Concord, Calif.-based peritioneal dialysis products firm on Aug. 30 approved merger plan with Fresenius USA that was announced Feb. 14 ("The Pink Sheet" Feb. 19, "In Brief"). New plan replaces one announced as preliminary agreement in June 1989 that was thrown out due to a break in Delmed's supply contract with National Medical Care ("The Pink Sheet" Oct. 30, 1989, T&G-9). Pursuant to plan, Fresenius USA and German parent Fresenius AG purchased $ 5 mil. in options to boost their equity stake in Delmed to approximately 80%, Delmed agreed to increase number of authorized shares from 100 mil. to 300 mil. and to increase number of issuable shares from 1.1 mil. to 5 mil.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS017996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel